Broadly neutralizing antibodies and monoclonal V2 antibodies derived from RV305 inhibit capture and replication of HIV-1

被引：0

作者：

Kim, Jiae ^{[1
,2
]}

Villar, Zuzana ^{[1
,2
]}

Jobe, Ousman ^{[1
,2
]}

Rerks-Ngarm, Supachai ^{[3
]}

Pitisuttithum, Punnee ^{[4
]}

Nitayaphan, Sorachai ^{[5
]}

O'Connell, Robert J. ^{[6
]}

Ake, Julie A. ^{[7
]}

Vasan, Sandhya ^{[1
]}

Rao, Venigalla B. ^{[8
]}

Rao, Mangala ^{[2
]}

机构：

[1] US Mil HIV Res Program, Henry M Jackson Fdn Advancement Mil Med, 6720A Rockledge Dr, Bethesda, MD 20817 USA

[2] US Mil HIV Res Program, Walter Reed Army Inst Res, Ctr Infect Dis Res, Lab Adjuvant & Antigen Res, Silver Spring, MD 20910 USA

[3] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand

[4] Mahidol Univ, Fac Trop Med, Vaccine Trial Ctr, Salaya, Thailand

[5] Armed Forces Res Inst Med Sci, Bangkok, Thailand

[6] United States Army Med Component, Armed Forces Res Inst Med Sci, Bangkok, Thailand

[7] US Mil HIV Res Program, Walter Reed Army Inst Res, Ctr Infect Dis Res, Silver Spring, MD 20910 USA

[8] Catholic Univ Amer, Bacteriophage Med Res Ctr, Dept Biol, 620 Michigan Ave,NE, Washington, DC 20064 USA

来源：

VIROLOGY | 2024年 / 597卷

关键词：

Virus capture; Broadly neutralizing antibodies; V2; region; Monoclonal antibodies; Primary virus; HIV-1; vaccine; RV144; RV305; PBMCs; qRT-PCR; EFFICACY; INFECTION; AIDSVAX; REVEAL; BINDS; ALVAC;

D O I：

10.1016/j.virol.2024.110158

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

An important approach to stopping the AIDS epidemic is the development of a vaccine that elicits antibodies that block virus capture, the initial interactions of HIV-1 with the target cells, and replication. We utilized a previously developed qRT-PCR-based assay to examine the effects of broadly neutralizing antibodies (bNAbs), plasma from vaccine trials, and monoclonal antibodies (mAbs) on virus capture and replication. A panel of bNAbs inhibited primary HIV-1 replication in PBMCs but not virus capture. Plasma from RV144 and RV305 trial vaccinees demonstrated inhibition of virus capture with the HIV-1 subtype prevalent in Thailand. Several RV305 derived V2-specific mAbs inhibited virus replication. One of these RV305 derived V2-specific mAbs inhibited both virus capture and replication, demonstrating that it is possible to elicit antibodies by vaccination that inhibit virus capture and replication. Induction of a combination of such antibodies may be the key to protection from HIV-1 acquisition.

引用

下载

页数：8

共 50 条

[31] Broadly neutralizing antibodies against HIV-1: Templates for a vaccine
van Gils, Marit J.
Sanders, Rogier W.
VIROLOGY, 2013, 435 (01) : 46 - 56
[32] Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Caskey, Marina
Klein, Florian
Nussenzweig, Michel C.
NATURE MEDICINE, 2019, 25 (04) : 547 - 553
[33] Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
Marina Caskey
Florian Klein
Michel C. Nussenzweig
Nature Medicine, 2019, 25 : 547 - 553
[34] AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
van den Berg, Fiona T.
Makoah, Nigel A.
Ali, Stuart A.
Scott, Tristan A.
Mapengo, Rutendo E.
Mutsvunguma, Lorraine Z.
Mkhize, Nonhlanhla N.
Lambson, Bronwen E.
Kgagudi, Prudence D.
Crowther, Carol
Karim, Salim S. Abdool
Balazs, Alejandro B.
Weinberg, Marc S.
Ely, Abdullah
Arbuthnot, Patrick B.
Morris, Lynn
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2019, 14 : 100 - 112
[35] Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge
Julg, Boris
Tartaglia, Lawrence J.
Keele, Brandon F.
Wagh, Kshitij
Pegu, Amarendra
Sok, Devin
Abbink, Peter
Schmidt, Stephen D.
Wang, Keyun
Chen, Xuejun
Joyce, M. Gordon
Georgiev, Ivelin S.
Choe, Misook
Kwong, Peter D.
Doria-Rose, Nicole A.
Le, Khoa
Louder, Mark K.
Bailer, Robert T.
Moore, Penny L.
Korber, Bette
Seaman, Michael S.
Karim, Salim S. Abdool
Morris, Lynn
Koup, Richard A.
Mascola, John R.
Burton, Dennis R.
Barouch, Dan H.
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (406)
[36] Indirect Mechanisms of HIV-1 Evasion from Broadly Neutralizing Antibodies In Vivo
Herschhorn, Alon
ACS INFECTIOUS DISEASES, 2023, 9 (01): : 5 - 8
[37] Interplay Between Broadly Cross-Neutralizing V2 Monoclonal Antibodies and Autologous Viral Evolution
Bhiman, J. N.
Doria-Rose, N.
Moore, P. L.
Nonyane, M.
Karim, S. S. Abdool
Kwong, P. D.
Mascola, J. R.
Morris, L.
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2013, 29 (11) : A12 - A12
[38] BROADLY NEUTRALIZING MONOCLONAL-ANTIBODIES TO THE V3-REGION OF HIV-1 CAN BE ELICITED BY PEPTIDE IMMUNIZATION
WHITESCHARF, ME
POTTS, BJ
SMITH, LM
SOKOLOWSKI, KA
RUSCHE, JR
SILVER, S
VIROLOGY, 1993, 192 (01) : 197 - 206
[39] Requirements for the Induction of Broadly Neutralizing Antibodies against HIV-1 by Vaccination
A. N. Vzorov
L. V. Uryvaev
Molecular Biology, 2017, 51 : 819 - 829
[40] Structural and Biochemical Characterization of Cysteinylation in Broadly Neutralizing Antibodies to HIV-1
Omorodion, Oluwarotimi
Wilson, Ian A.
JOURNAL OF MOLECULAR BIOLOGY, 2021, 433 (24)

← 1 2 3 4 5 →